Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Celgene Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net income (loss) 1,691 1,571 1,545 1,073 1,082 1,045 846 (81) 988 1,101 932 429 171 598 801 561 (34) 356 719 614 509 598 280
Depreciation 48 47 47 41 40 41 38 34 34 34 32 32 31 29 29 28 29 30 28 26 26 27 26
Amortization 123 111 110 129 129 129 88 82 81 90 84 408 139 211 114 118 88 68 69 66 198 67 72
Impairment charges 1 3 27 1,628 1 50
Deferred income taxes 59 (38) (41) 42 33 9 (52) (1,135) (9) (106) (80) (87) (90) (123) (43) 380 (161) (146) (107) (24) (68) (101) (80)
Change in value of contingent consideration and success payments (1) (47) 30 (55) 97 7 (30) (1,425) 49 (13) 39 9 23 (44) 33 9 (7) (29) 19 38 2 1 9
Gain on sale of business (38)
Net (gain) loss on sales of debt securities available-for-sale 18 (43) (3) (15) (7) 1 2 (86) 1 1 3
Fair value adjustments on equity investments 222 147 (269) 513 124 5 (959)
Share-based compensation expense 176 225 257 190 239 284 208 162 159 170 153 155 148 158 147 150 150 148 129 128 111 103 104
Share-based employee benefit plan expense 13 11 9 (1) 13 12 10 12 9 11 9 11 7 9 8 11 12 10 7
Derivative instruments 23 8 14 (19) 30 (22) 58 (46) 53 7 (24) 208 (36) 21 8 (36) 3 (7) (49) (11) (18) 6
Other, net (36) (40) 2 (1) (4) (12) 2 (6) 28 (46) (1) (11) 4 (2) 1 22 (4) 1 (10) 1 (3) (1)
Accounts receivable 54 (114) (271) 47 (68) (110) (47) (97) (64) (92) 17 (79) (63) (104) 23 (159) (5) (81) (60) (120) 16 (52) (10)
Inventory 12 (21) 16 51 45 (20) 6 (5) (5) (22) (10) 7 (17) (20) (26) (24) (8) (27) 7 (23) (15) (12) (7)
Other operating assets (171) 21 50 319 (51) (152) (171) 212 (101) (213) 29 (43) 37 62 39 (309) 29 (20) (26) (3) 19 7 30
Accounts payable and other operating liabilities 13 99 (28) 356 78 75 (219) 245 (191) 584 (365) 455 109 185 (130) 277 179 18 59 178 94 (132) 112
Income tax payable (4) 234 35 (371) 156 (168) (10) 2,064 132 29 4 84 14 16 (3) 17 11 17 16 11 3 14 11
Payment of contingent consideration (16) (13) (22) (9) (9) (5)
Deferred revenue (14) (35) (2) (6) 27 28 (8) (3) 22 1 (5) 15 (5) 2 (12) 18 29 2 (3) 3 4 4
Change in current assets and liabilities, excluding the effect of acquisitions and disposals (110) 168 (213) 396 187 (347) (471) 2,416 (207) 286 (324) 411 95 135 (95) (209) 225 (65) (2) 30 121 (171) 135
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities 481 596 (69) 1,270 842 184 (1,171) 1,770 100 515 (79) 914 551 338 174 497 319 (72) 138 219 392 (82) 277
Net cash provided by (used in) operating activities 2,172 2,167 1,476 2,343 1,924 1,229 (325) 1,689 1,088 1,616 853 1,343 723 936 975 1,058 285 284 857 833 901 516 557
Proceeds from sales of debt securities available-for-sale 602 113 261 5 143 37 3,203 2,678 1,233 1,791 266 91 114 114 314 138 2,082 500 1,080 514 518 556 588
Purchases of debt securities available-for-sale (3) (62) (428) (435) (130) (48) (62) (1,762) (3,305) (1,620) (1,791) (720) (128) (147) (285) (190) (572) (448) (679) (524) (581) (790) (767)
Capital expenditures (68) (60) (69) (98) (64) (80) (88) (103) (44) (70) (62) (66) (67) (44) (60) (141) (51) (53) (42) (49) (40) (37) (25)
Proceeds from sales of equity investment securities 17 1 2 41 55 (12) 5 27 2 2 11 7 78 7
Purchases of equity investment securities (11) (35) (61) (73) (21) (37) (118) 297 (236) (79) (77) (10) (33) (10) (79) (56) (16) (173) (28) (9) (36) (5) (18)
Payments for acquisition of businesses, net of cash acquired (8,648) (116) (7,579) (710)
Payment for acquisition of intangible asset (400)
Other (27) (4) 4 (1) (3) (2) (3) (4) (21) 1
Net cash (used in) provided by investing activities 137 (43) (295) (601) (31) (128) (5,658) 1,098 (2,374) 45 (1,660) (704) (112) (75) (110) (361) (6,138) (98) 338 (73) (159) (986) (220)
Payment for treasury shares (3,396) (2,700) (2,908) (114) (518) (293) (134) (320) (296) (1,410) (683) (577) (985) (1,013) (541) (252) (614) (1,569)
Proceeds from short-term borrowing 780 3,114 1,815 100 3,881 1,260 881 90 130 202 775 1,460
Principal repayments on short-term borrowing 1 (1,776) (2,119) (1,815) (100) (4,582) (1,421) (20) (190) (130) (294) (1,453) (1,135)
Proceeds from issuance of long-term debt 4,452 2,972 496 7,913 2,471
Principal repayments on current portion of long-term debt (500) (1,404) (500) (514)
Net proceeds (payments) from common equity put options 2 3 3 (19) 4 1 5 5 1 4 1
Payment of contingent consideration (24) (58) (40) (41) (11) (15)
Net proceeds from share-based compensation arrangements 102 177 84 15 83 2 44 48 250 203 184 168 115 14 62 48 100 (10) 114 92 111 35 59
Excess tax benefit from share-based compensation arrangements 59 48 57 25 57 70 90 85 104 56 60 30
Net cash provided by (used in) financing activities 102 (347) 26 16 (913) (2,399) 1,756 (1,292) 132 (315) (109) 53 (156) (223) (1,320) (1,813) 7,349 (43) (908) (352) (176) 1,279 (1,169)
Effect of currency rate changes on cash and cash equivalents (21) 4 (8) (4) (3) (18) 33 7 5 41 19 (44) 5 (20) 20 (20) (10) 20 (40) (29) (43) 15 (6)
Net increase (decrease) in cash and cash equivalents 2,390 1,781 1,199 1,754 977 (1,316) (4,194) 1,502 (1,149) 1,387 (897) 647 459 618 (435) (1,136) 1,486 163 246 379 523 823 (838)

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Celgene Corp. net cash provided by (used in) operating activities increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Celgene Corp. net cash (used in) provided by investing activities increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Celgene Corp. net cash provided by (used in) financing activities decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.